Kertu K.
- Country
- Estonia
- Department
- Oncology Clinic
Research Overview
- Pharmacokinetic Comparison of FYB206 and Pembrolizumab in Adjuvant Treatment of Stage IIB, IIC, or III Melanoma Post-Resection
- Phase 3 Randomized Study of Perioperative Dostarlimab vs. Standard of Care in Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- Phase 3 Randomized, Double-Blind Study of Belrestotug and Dostarlimab Versus Pembrolizumab in PD-L1 High Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 31 of 251 partner sites.
Specializations
Oncology Focus
This investigator specializes in treating advanced forms of melanoma and non-small cell lung cancer, with particular expertise in immunotherapy approaches for these conditions.
- Advanced Melanoma Management
- NSCLC Treatment Strategies
- Immunotherapy Applications
Their research encompasses adjuvant therapy for Stage IIB, IIC, and III melanoma following surgical intervention, as well as treatment approaches for patients with PD-L1 high expressing tumors.
Therapeutic Expertise
The investigator focuses on innovative immunotherapeutic combinations and comparative treatment approaches in oncology.
- Novel Immunotherapy Combinations
- Post-Surgical Treatment Strategies
- Targeted Cancer Therapies
Their work involves evaluating therapeutic options for patients with specific biomarker profiles, particularly those with high PD-L1 expression levels.
Clinical Interests
The investigator specializes in developing treatment protocols for resectable cancers and implementing novel therapeutic approaches for advanced malignancies.
- Biomarker-Driven Treatment
- Adjuvant Therapy Protocols
- Comparative Treatment Studies
Their expertise extends to managing both early-stage and advanced cancers, with a focus on personalized treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.